Lynparza, First In A New Class Of Cancer Drugs, Is Surprisingly Active In A Wide Range Of Tumors
So far, the studies demonstrate that Lynparza has activity in cancer patients with and without inherited BRCA mutations.
So far, the studies demonstrate that Lynparza has activity in cancer patients with and without inherited BRCA mutations.
A low Oncotype DCIS score predicts a low chance that non-invasive breast cancer will recur. The study supports that many
Oncotype Test Could Reduce Overtreatment Of Early Stage Breast Cancer Read More »
First, you need awareness. In many world regions, fatalism is still an obstacle. Second, you need a delivery system. Third…
To Address Breast Cancer Globally, 3 Things Are Essential Read More »
Employment and money concerns haunt many people with all kinds of cancer, nation-wide, during and after treatment.
Collateral Damage: How A Cancer Diagnosis Hurts Employment And Finances Read More »